Medicina
Departamento
New York University Langone Medical Center
Nueva York, Estados UnidosPublicaciones en colaboración con investigadores/as de New York University Langone Medical Center (39)
2023
-
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
New England Journal of Medicine, Vol. 389, Núm. 22, pp. 2039-2051
-
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up
Annals of Oncology, Vol. 34, Núm. 3, pp. 289-299
2022
-
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction
Circulation, Vol. 146, Núm. 16, pp. 1196-1206
-
Allergen immunotherapy and/or biologicals for IgE-mediated food allergy: A systematic review and meta-analysis
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 6, pp. 1852-1862
-
Erratum: Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (European journal of human genetics : EJHG (2022) 30 3 (349-362))
European journal of human genetics : EJHG
-
Polygenic risk modeling for prediction of epithelial ovarian cancer risk
European journal of human genetics : EJHG, Vol. 30, Núm. 3, pp. 349-362
-
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
Clinical Cancer Research, Vol. 28, Núm. 10, pp. 2050-2060
2021
-
Global Chronic Total Occlusion Crossing Algorithm: JACC State-of-the-Art Review
Journal of the American College of Cardiology, Vol. 78, Núm. 8, pp. 840-853
-
Management in the ICU
ERS Monograph, Vol. 2021, Núm. 94, pp. 124-143
-
Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: The COMBAT/ KEYNOTE-202 trial
Clinical Cancer Research, Vol. 27, Núm. 18, pp. 5020-5027
-
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer
Future Oncology, Vol. 17, Núm. 2, pp. 137-149
2020
-
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder
Multiple Sclerosis and Related Disorders, Vol. 38
-
Essential tremor-plus: a controversial new concept
The Lancet Neurology, Vol. 19, Núm. 3, pp. 266-270
-
Long-term outcomes in KEYNOTE-052: Phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer
Journal of Clinical Oncology, Vol. 38, Núm. 23, pp. 2658-2666
-
Overall survival with ribociclib plus fulvestrant in advanced breast cancer
New England Journal of Medicine, Vol. 382, Núm. 6, pp. 514-524
-
Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status
European urology oncology, Vol. 3, Núm. 3, pp. 351-359
-
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study
Breast, Vol. 54, pp. 148-154
2019
-
New filovirus disease classification and nomenclature
Nature Reviews Microbiology
-
Publisher Correction: Shared heritability and functional enrichment across six solid cancers (Nature Communications, (2019), 10, 1, (431), 10.1038/s41467-018-08054-4)
Nature Communications
-
Shared heritability and functional enrichment across six solid cancers
Nature Communications, Vol. 10, Núm. 1